Charles J. Dockendorff - Sep 5, 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
Director
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Dockendorff
Stock symbol
HAE
Transactions as of
Sep 5, 2023
Transactions value $
-$895,651
Form type
4
Date filed
9/7/2023, 04:23 PM
Previous filing
Aug 18, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Sale -$896K -10.2K -82.11% $87.68 2.23K Sep 5, 2023 Direct F1, F2, F3
holding HAE Common Stock 17.9K Sep 5, 2023 Spouse?s Revocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing 10b5-1 trading plan dated May 26, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.19 to $88.01, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 This number includes unvested restricted stock units previously reported.